At a Glance
Dosage
Only in 25N-NBOMe
sublingual
| Level | Dose |
|---|---|
| Threshold | 100 µg |
| Light | 100–300 µg |
| Common | 300–800 µg |
| Strong | 800–1300 µg |
Only in 1cP-MiPLA
oral
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–150 µg |
| Common | 150–200 µg |
| Strong | 200–250 µg |
| Heavy |
Duration
Only in 25N-NBOMe
sublingual
Total: 5 hrs – 10 hrsPeak
Offset
Afterglow
Onset45 min – 1.3 hrs
Peak2 hrs – 3 hrs
Offset2 hrs – 3 hrs
Afterglow5 hrs – 10 hrs
Only in 1cP-MiPLA
oral
Effects
Safety
Interaction: 25N-NBOMe + 1cP-MiPLA
No direct interaction data available between these substances. This does not mean the combination is safe.
25N-NBOMe — Dangerous Interactions
No dangerous interactions recorded.
1cP-MiPLA — Dangerous Interactions
No dangerous interactions recorded.
Frequently Asked Questions
What is the difference between 25N-NBOMe and 1cP-MiPLA?
25N-NBOMe is classified as a Psychedelic (Substituted phenethylamines) while 1cP-MiPLA is classified as a Psychedelic (Lysergamides). They share 41 effects in common, with 19 effects unique to 25N-NBOMe and 29 unique to 1cP-MiPLA.
Is it safe to combine 25N-NBOMe and 1cP-MiPLA?
There is no direct interaction data available for combining 25N-NBOMe and 1cP-MiPLA. This does not mean the combination is safe. Always exercise caution and research thoroughly.
Which is stronger, 25N-NBOMe or 1cP-MiPLA?
25N-NBOMe and 1cP-MiPLA are typically administered via different routes, making a direct potency comparison difficult. They belong to different pharmacological profiles and should not be compared by dose alone.